Table 1 Patient characteristics and muscle and adipose tissue response to cholangiocarcinoma therapy

From: Skeletal muscle anabolism is a side effect of therapy with the MEK inhibitor: selumetinib in patients with cholangiocarcinoma

 

Phase II study cholangiocarcinoma selumetinib therapygroup

Cholangiocarcinoma standard therapy group

Patients, n

20

30

Gender, male, %

30

56.7

Stage

100% Stage IV

100% Stage IV

Scan interval, days median (s.e.)

91.5 (6.7)

85.5 (51.1)

Time to death, days median (s.e.)

295 (4.5)a

277 (56.1)a

Age, mean±s.d.

54.5±14.4

58.6±12.2

Body mass index, kg m−2, mean±s.d.#

31.2±9.4

25.9±5.0

Muscle change/100 days cm 2

 Mean (s.d.)

13.80 (11.9)a

−7.3 (14.3)b

 Estimated, kg

2.3

−1.2

Adipose tissue change/100 days cm 2

 Mean (s.d.)

−97.2 (413.2)a

−56.2 (85.4)a

 Estimated kg

−6.6

−3.8

  1. a, b comparison of tumour groups, means followed by different alphabets are different (P<0.05). Estimated kilograms of muscle and adipose are calculated from the regression equations reported by Shen et al (2004).
  2. Body mass index available for N=15 cholangiocarcinoma patients.
Back to article page